$0.59 EPS Expected for BioSpecifics Technologies Corp. (BSTC); Avation PLC (LON:AVAP) Covered By 3 Bulls

April 29, 2018 - By Matt Maslow

Among 3 analysts covering Avation (LON:AVAP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Avation had 14 analyst reports since September 7, 2015 according to SRatingsIntel. On Monday, April 11 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The firm earned “Buy” rating on Friday, February 26 by WH Ireland. Beaufort Securities maintained the shares of AVAP in report on Tuesday, October 13 with “Speculative Buy” rating. Canaccord Genuity maintained the shares of AVAP in report on Monday, February 26 with “Buy” rating. The rating was maintained by WH Ireland on Monday, September 7 with “Buy”. The firm has “Buy” rating by WH Ireland given on Friday, October 16. Beaufort Securities maintained it with “Speculative Buy” rating and GBX 178 target in Monday, September 14 report. Canaccord Genuity maintained it with “Buy” rating and GBX 300 target in Monday, November 27 report. The firm earned “Buy” rating on Tuesday, November 17 by WH Ireland. The stock has “Speculative Buy” rating by Beaufort Securities on Tuesday, September 22. See Avation PLC (LON:AVAP) latest ratings:

26/02/2018 Broker: Canaccord Genuity Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
18/12/2017 Broker: Canaccord Genuity Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
27/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
20/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: GBX 300.00 Initiates Starts




Analysts expect BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report $0.59 EPS on May, 9.They anticipate $0.13 EPS change or 28.26% from last quarter’s $0.46 EPS. BSTC’s profit would be $4.25 million giving it 18.11 P/E if the $0.59 EPS is correct. After having $0.51 EPS previously, BioSpecifics Technologies Corp.’s analysts see 15.69% EPS growth. The stock increased 0.52% or $0.22 during the last trading session, reaching $42.73. About 15,486 shares traded. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has declined 15.60% since April 29, 2017 and is downtrending. It has underperformed by 27.15% the S&P500.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $307.62 million. The firm offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 27.57 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Among 2 analysts covering BioSpecifics Technologies Corp (NASDAQ:BSTC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioSpecifics Technologies Corp had 7 analyst reports since March 8, 2016 according to SRatingsIntel. The company was maintained on Thursday, August 10 by H.C. Wainwright. H.C. Wainwright maintained BioSpecifics Technologies Corp. (NASDAQ:BSTC) on Monday, December 11 with “Buy” rating. Rodman & Renshaw initiated it with “Buy” rating and $60 target in Tuesday, March 8 report. H.C. Wainwright maintained BioSpecifics Technologies Corp. (NASDAQ:BSTC) on Monday, November 13 with “Buy” rating. As per Tuesday, December 26, the company rating was maintained by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, February 7 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, March 13 by H.C. Wainwright.

Investors sentiment increased to 1.22 in 2017 Q4. Its up 0.14, from 1.08 in 2017Q3. It improved, as 8 investors sold BioSpecifics Technologies Corp. shares while 28 reduced holdings. 16 funds opened positions while 28 raised stakes. 3.63 million shares or 1.80% less from 3.70 million shares in 2017Q3 were reported. Hanson Mcclain stated it has 200 shares. Architects accumulated 0% or 360 shares. Retail Bank Of America De reported 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Millennium Management Ltd Liability Co reported 0% stake. Sg Americas Secs Ltd Limited Liability Company owns 6,911 shares. Acadian Asset Mngmt Limited Liability Company has 0.02% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 112,234 shares. Jefferies Limited Liability holds 4,758 shares or 0% of its portfolio. Numeric Invsts Ltd has 37,123 shares for 0.01% of their portfolio. Jw Asset Management Ltd Llc holds 3.4% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 73,649 shares. Aqr Mngmt Llc stated it has 135,493 shares. D E Shaw & Incorporated stated it has 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Eagle Asset Mgmt invested in 133,493 shares or 0.03% of the stock. Meeder Asset Mgmt has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 487 shares. Northern Trust has 87,857 shares. Los Angeles Mgmt And Equity Rech Inc reported 4,859 shares.

Avation PLC, together with its subsidiaries, operates as a commercial passenger aircraft leasing firm worldwide. The company has market cap of 142.78 million GBP. It operates in two divisions, Aircraft Leasing and Business Procurement. It has a 6.79 P/E ratio. The firm owns a range of commercial passenger aircraft; and supplies new and refurbished aircraft parts.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: